AX-2025-019150 · NAD+ · GSP lot GSP-2503-B3620

Section 1

Results

Measured against the index acceptance specification for the non-peptide adjuncts class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 25 min gradient, 214 nm	99.77	% area	≥ 97.0	PASS
Total impurities	RP-HPLC, sum of reported peaks	0.23	% area	≤ 3.0	PASS
Largest single impurity	RP-HPLC — α-NAD anomer	0.15	% area	≤ 1.00	PASS
Identity	not ordered on this submission	not determined	—	required for VERIFIED status	NOT TESTED
Peptide content	not ordered on this submission	not determined	—	required to check label claim	NOT TESTED
Water content	Karl Fischer, coulometric, duplicate	9.62	%	≤ 10.0	PASS
Counter-ion	no ionisable counter-ion expected	N/A	—	not applicable	NOT TESTED
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.91	%	—	NOT TESTED
Endotoxin	not ordered on this submission	not determined	—	≤ 5.0	NOT TESTED
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White cake, partially collapsed	—	white to off-white intact cake	FAIL
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	8.14	—	2.5 – 8.0	FAIL
Retention time (observed)	RP-HPLC, 25 min gradient	3.41	min	3.52 ± 0.25 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.09	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	83,541	—	≥ 20,000	PASS
Resolution to nearest impurity	vs α-NAD anomer	3.10	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 25 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 83,541, and skew follows the reported asymmetry factor of 1.09. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.15 % impurity against a 99.77 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	NAD+ — main peak	3.41	4,849,131	99.77	—
2	α-NAD anomer	3.56	7,290	0.15	0.000
3	NADH (reduced, +2 Da)	3.69	2,916	0.06	+2.016
4	ADP-ribose (−121 Da)	3.19	972	0.02	-121.040
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	99.83	99.77	divergence +0.06 pp vs batch median
Total impurities (% area)	0.17	0.23
Largest single impurity (% area)	0.06	0.15
Water (%)	not stated	9.62
Counter-ion (%)	4.5	N/A
Peptide content (%w/w)	91.4	not determined
Endotoxin (EU/mg)	0.43	not determined
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Retail purchase → submitter (ambient, 21 d) → laboratory (courier, cold pack, 7 d) → assay.
Assay date: 22 Aug 2025
Submitted to the index: 30 Aug 2025
Laboratory: Medutest, Ljubljana, Slovenia
Method basis: 25 min gradient · unit-resolution MS
Verification status: PARTIAL

What this report does not establish

That the compound is the compound named. No identity confirmation was ordered on this submission. A purity figure describes chromatographic homogeneity of whatever eluted; it does not name it.
How much of the named compound is in the vial. Peptide content was not determined, so recovered mass cannot be calculated and the label claim cannot be checked.
That the material is free of bacterial endotoxin. Endotoxin was not measured. No chromatographic result bears on it.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 3

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

valley_drop30 Aug 2025

Largest single impurity is α-NAD anomer at 0.15 % area, and it is the only named peak above 0.1 %. The integration is unambiguous and 99.77 % can be taken at face value.

wide_iqr30 Aug 2025

A single result at 99.77 % is one draw. What makes a supplier's process legible is the spread across its lots, and that is on the scorecard rather than here. This record is one good point in a distribution worth reading whole.

retest_date30 Aug 2025

A retest date on the certificate would tell you what the supplier is actually asserting about stability. Purity at 99.77 % on assay day is a starting condition, not a shelf life.

Section 7

Related records

Same batch — lot GSP-2503-B3620 n=3

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2025-019149	GSP-2503-B3620	Janoshik	2025-Q3	99.83	9.91	92.2	Buyer-sourced	0	PASS
AX-2025-019151	GSP-2503-B3620	Janoshik	2025-Q3	99.74	9.26	94.8	Buyer-sourced	0	PASS

Batch rollup and reproducibility assessment →

Cross-sections

Other recent NAD+ records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041208	WWB	WWB-2601-V1583	VendorInvestigate	2026-Q2	99.47	11.38	100.9	Buyer-sourced	0	FAIL
AX-2026-041209	WWB	WWB-2601-V1583	Nordanalyt	2026-Q2	99.47	11.40	106.7	Buyer-sourced	0	FAIL
AX-2026-041210	WWB	WWB-2601-V1583	Nordanalyt	2026-Q2	99.66	11.01	91.9	Buyer-sourced	0	FAIL
AX-2026-041211	WWB	WWB-2601-V1583	Janoshik	2026-Q2	99.72	10.94	93.5	Buyer-sourced	0	FAIL
AX-2026-041213	WWB	WWB-2601-V1583	VendorInvestigate	2026-Q2	99.33	11.41	—	Buyer-sourced	0	FAIL
AX-2026-041212	WWB	WWB-2601-V1583	Janoshik	2026-Q2	99.93	10.36	88.5	Laboratory-retained	1	FAIL
AX-2025-019628	TFC	TFC-2505-C1792	Janoshik	2025-Q3	99.72	11.19	92.6	Buyer-sourced	0	FAIL
AX-2025-019134	GSP	GSP-2507-A3926	Janoshik	2025-Q3	98.84	11.68	—	Buyer-sourced	0	FAIL

Other recent GSP records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041831	Survodutide	GSP-2603-E3156	Kestrel	2026-Q3	99.91	5.50	93.2	Buyer-sourced	0	PASS
AX-2026-041836	Survodutide	GSP-2603-E3156	Janoshik	2026-Q3	98.65	5.34	90.3	Buyer-sourced	0	PASS
AX-2026-041837	Survodutide	GSP-2603-E3156	Janoshik	2026-Q3	98.33	5.37	—	Buyer-sourced	0	PASS
AX-2026-041833	Survodutide	GSP-2603-E3156	Janoshik	2026-Q3	98.08	4.91	99.3	Buyer-sourced	0	PASS
AX-2026-041832	Survodutide	GSP-2603-E3156	VendorInvestigate	2026-Q3	98.01	5.14	99.5	Buyer-sourced	0	PASS
AX-2026-041835	Survodutide	GSP-2603-E3156	Nordanalyt	2026-Q3	98.34	5.74	89.0	Buyer-sourced	1	MARGINAL
AX-2026-041834	Survodutide	GSP-2603-E3156	VendorInvestigate	2026-Q3	97.92	5.95	—	Buyer-sourced	0	PASS
AX-2026-041838	Survodutide	GSP-2603-E3156	PeptideMeter	2026-Q3	98.30	5.01	102.4	Buyer-sourced	0	PASS